Madrigal Pharmaceuticals ...

NASDAQ: MDGL · Real-Time Price · USD
360.74
-10.63 (-2.86%)
At close: Aug 15, 2025, 10:16 AM

Madrigal Pharmaceuticals Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
180.13M n/a n/a n/a
Cost of Revenue
6.23M 527K 467K 405K
Gross Profit
173.9M -527K -467K -405K
Operating Income
-497.88M -380.5M -293.57M -242.48M
Interest Income
46.65M 19.58M 2.19M 363K
Pretax Income
-465.89M -373.63M -295.35M -241.85M
Net Income
-465.89M -373.63M -295.35M -241.85M
Selling & General & Admin
435.06M 108.15M 48.13M 37.32M
Research & Development
236.72M 271.82M 245.44M 205.16M
Other Expenses
n/a n/a n/a 273K
Operating Expenses
671.77M 380.5M 293.57M 242.48M
Interest Expense
14.67M 12.71M 3.96M n/a
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
678.01M 380.5M 293.57M 242.48M
Income Tax Expense
n/a n/a n/a -768K
Shares Outstanding (Basic)
21.27M 18.69M 17.14M 16.54M
Shares Outstanding (Diluted)
21.27M 18.69M 17.14M 16.54M
EPS (Basic)
-21.9 -19.99 -17.23 -14.63
EPS (Diluted)
-21.9 -19.99 -17.23 -14.63
EBITDA
-450.13M -379.97M -290.92M -242.08M
EBIT
-451.22M -380.5M -291.39M -242.48M
Depreciation & Amortization
1.1M 527K 467K 405K